Research programme: anti-EGFR killer immunoglobulin-like receptor based chimeric antigen receptor T cell therapies - Verismo Therapeutics
Alternative Names: KIR-CAR-EGFRvIII - Verismo Therapeutics; SynKIR-EGFRvIIILatest Information Update: 19 Oct 2021
At a glance
- Originator Verismo Therapeutics
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Glioblastoma
Most Recent Events
- 18 Oct 2021 Early research in Glioblastoma in USA (Parenteral) as of October 2021 (Verismo Therapeutics pipeline; October 2021)
- 01 Apr 2021 HBL acquires manufacturing and marketing license from Verismo Therapeutics
- 01 Apr 2021 Verismo Therapeutics in-licenses KIR-CAR platform technology from University of Pennsylvania before April 2021